NewswireToday - /newswire/ -
Redbank, NJ, United States, 2013/07/23 - American CryoStem announced that the Corporation today Company has been invited to present at the Financial Services Exchange (FSX) conference to be held at the Ritz-Carlton, Fort Lauderdale, July 25-27 (OTCQB: CRYO) - AmericanCryoStem.com.
American CryoStem Corporation, a leading strategic developer, marketer and global licensor of patented adipose tissue-based cellular technologies for the Regenerative and Personalized Medicine industries, today announced that the Company has been invited to present at the Financial Services Exchange (FSX) conference to be held at the Ritz-Carlton, Fort Lauderdale, July 25-27, 2013.
FSX is a premier investment conference organization founded in 1983. Four times per year, FSX meets in a different major U.S city where the FSX connects emerging growth companies with a nationwide network of financial investment professionals. FSX brings the CEOs and executive officers of presenting companies together with the principals and key decision makers of Broker/Dealers and other financial firms.
FSX provides a forum where CEOs seeking capital and/or market support can come to showcase their companies in a dedicated environment that is conducive to networking and building financial relationships.
EVENT AT A GLANCE
WHO: John Arnone Chairman and CEO
Anthony Dudzinski COO
WHEN: Thursday, July 25, 2013
3:23 PM ET 3:33 PM ET
WHERE: The Ritz-Carlton, Fort Lauderdale
1 North Fort Lauderdale Beach Boulevard
About American CryoStem Corporation
A pioneer in the fields of Regenerative and Personalized Medicine, American CryoStem (americancryostem.com) is a developer, marketer and global licensor of patented adipose tissue based cellular technologies and related proprietary services with a focus on clinical processing, commercial bio-banking and application development for adipose (fat) tissue and autologous adipose-derived regenerative cells (ADRCs). The Company maintains a strategic portfolio of intellectual property and patent applications that form its Adipose Tissue Processing Platform, which supports and promotes a growing pipeline of biologic products and processes, clinical services and international licensing opportunities. Through its ACS Laboratories division, the Company operates an FDA registered, cGMP compliant human tissue processing, cryo-storage and cell culture and differentiation media development facility in Mount Laurel, New Jersey.